logo
logo
Vor Biopharma Inc.

Vor Biopharma Inc.

NASDAQ•VOR
CEO: Dr. Robert Ang M.B.A., M.D., MBBS
セクター: Healthcare
業種: Biotechnology
上場日: 2021-02-05
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
連絡先情報
100 Cambridgepark Drive, Suite 101, Cambridge, MA, 02140, United States
617-655-6580
www.vorbio.com
時価総額
$89.58M
PER (TTM)
-0.0
33.3
配当利回り
--
52週高値
$65.80
52週安値
$2.62
52週レンジ
17%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$121.63+1420.38%
直近4四半期の推移

フリーCF

-$53.91M+131.17%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Cash Position Cash, equivalents, and securities total $170.5M USD as of September 30, 2025; financing provided $196.0M USD net cash.
Telitacicept License Impact R&D expenses surged $234.4M USD to $302.3M USD for nine months due to $222.6M USD upfront license charge.
Significant Net Loss Widens Nine-month net loss reached $(2.42B) USD, substantially wider than $(86.2M) USD loss reported in prior year period.
Major Warrant Liability Change Change in fair value of liability warrants resulted in a $(2.09B) USD loss impacting nine-month results significantly.

リスク要因

Future Funding Requirements Incurred significant net losses since inception; continued operations depend on raising substantial additional capital when needed.
Lead Candidate Dependency Business substantially dependent on successful development, approval, and commercialization of lead candidate, telitacicept.
Massive Warrant Liability Outstanding liability-classified warrants total $2.38B USD as of September 30, 2025, posing significant balance sheet risk.
Clinical Trial Execution Risks Success relies on timely patient enrollment and favorable results in global Phase 3 trials for gMG indication.

見通し

Post-Period Financing Secured Expect cash runway into Q2 2027 based on $49.8M USD ATM sales in October and $93.7M USD offering in November.
Advance Telitacicept Development Broader plan includes exploring telitacicept development in additional indications like Sjögren's disease globally.
Increased Operating Expenses Expect substantial expense increases continuing clinical development, regulatory activities, and scaling commercial infrastructure if approved.
Maintain IP Protection Focus on maintaining, expanding, and defending intellectual property portfolio for product candidates against third-party challenges.

同業比較

売上高 (TTM)

Heron Therapeutics, Inc.HRTX
$155.10M
+12.6%
Coherus BioSciences, Inc.CHRS
$83.57M
-63.6%
Alector, Inc.ALEC
$69.05M
+12.3%

粗利益率 (最新四半期)

Alector, Inc.ALEC
100.0%
+0.0pp
Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Fate Therapeutics, Inc.FATE
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PEPG$466.80M-2.4-84.1%9.2%
FBRX$385.58M-10.6-75.6%0.0%
TARA$251.99M-5.2-35.1%2.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日
|
EPS:-$1.14
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月13日|
    売上高: $0.00+0.0%
    |
    EPS: $-121.63+1420.4%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-251.20+2963.4%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-5.20-42.2%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月20日|
    売上高: $0.00+0.0%
    |
    EPS: $-34.00+2.9%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-8.00-18.4%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $0.00+0.0%
    |
    EPS: $-8.20-8.9%
    不明

  • Form 10-Q/A - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年8月8日|
    売上高: $0.00+0.0%
    |
    EPS: $-9.00+12.5%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|修正版データを参照